Yahoo! Finance Search - Finance Home - Yahoo! - Help

Monday, January 23 2017 9:29am ET - U.S. Markets open in 1 minute.
Industry Center - Drugs - Generic
Industry Center > Drugs - Generic > News
More On This Industry
· Summary
News
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Biotechnology
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Manufacturers - Other
· Drug Related Products
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
 
Drugs - Generic News
Latest News
Saturday, Jan 21, 2017
·IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
- Fri Jan 20
·SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Agile Therapeutics, Inc. and Certain Officers – AGRX
GlobeNewswire - Fri Jan 20
·Supernus misses 3Q revenue forecasts
AP - Fri Jan 20
·CRUCIAL SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
- Fri Jan 20
Friday, Jan 20, 2017
·INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Agile Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Fri Jan 20
·JP Morgan Downgrades Teva
at Investopedia - Fri Jan 20
·Developer of cannabinoid patch seeking $50M from stock sale
at bizjournals.com - Fri Jan 20
·Synergy Pharmaceuticals Secures Approval for Linzess Competitor
at TheStreet.com - Fri Jan 20
·FDA OKs Synergy Pharmaceuticals Constipation Drug
at Investopedia - Fri Jan 20
·EpiPen rival to be offered free to many but high price for insurers
Reuters - Thu Jan 19
·U.S. health agency tells Grassley there is no EpiPen deal yet
Reuters - Thu Jan 19
·Agile Therapeutics to Present at Noble Capital Markets’ Thirteenth Annual Investor/Equity Conference
GlobeNewswire - Thu Jan 19
Thursday, Jan 19, 2017
·U.S. health agency tells Grassley there is no EpiPen settlement yet
Reuters - Thu Jan 19
·Mallinckrodt plc -- Moody's: Mallinckrodt's settlement with the FTC is credit negative
- Thu Jan 19
·NBIX: Phase 2 Study of INGREZZA™ in Adults with Tourette Syndrome Fails to Hit Primary Endpoint
- Thu Jan 19
·Kaleo Inc. says its competitor to Mylan's EpiPen will be available for $360 starting Feb. 14
at MarketWatch - Thu Jan 19
·Pittsburgh Law Office of Alfred G. Yates Jr., PC Announces Investigation of Carbylan Therapeutics, Inc. (CBYL), currently known as KalVista Pharmaceuticals, Inc. (KALV)
PR Newswire - Thu Jan 19
·Mallinckrodt shares reverse some losses after FTC settlement on $34,000 drug
at MarketWatch - Thu Jan 19
·Mallinckrodt: Time to Buy?
at Barrons.com - Thu Jan 19
·Bull-Bear Battle Coming to a Head for Allergan
at Investopedia - Thu Jan 19
More Latest News...
  

RSS Feeds

Add headlines to your
personalized My Yahoo Page
( About My Yahoo and RSS )

Drugs - Generic Headlines
More Finance RSS Feeds


Copyright © 2017 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2017 Morningstar, Inc. All Rights Reserved. Company information © 2017 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2017, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?